Module 05a. Cardiovascular PET Tracers - Part a-Cardiovascular PET Tracers (Slides)

Cardiovascular PET Tracers (Slides)

Pdf Summary

This document explores Cardiovascular PET Tracers with a focus on physics, physiology, and unique characteristics. Key points covered include defining radiotracers, describing PET flow tracers, and comparing strengths and weaknesses of available PET flow tracers. PET radiotracers, including N13-Ammonia, Rubidium82, and F18-Flurpiridaz, are discussed in terms of their physics, biology, and imaging potential. The importance of compartmental modeling in quantifying processes like myocardial blood flow (MBF) is highlighted. Different PET tracers have varying strengths and weaknesses affecting factors like spatial resolution, contrast resolution of defects, and radiation exposure. Tests with tracers like N13-Ammonia and O15-Water are FDA approved, while F18-Flurpiridaz is undergoing Phase III trials. Tracer characteristics, such as extraction fraction (ExF) and retention fraction (RF), impact diagnostic accuracy and contrast resolution of perfusion defects. PET imaging surpasses SPECT imaging due to characteristics of PET tracers, higher energy, and shorter positron range leading to better spatial resolution. Recommendations for optimal tracer use in patient-centered imaging and protocols for stress testing and rest imaging are also discussed, emphasizing the importance of accurate quantification of processes like MBF for improved diagnostic and prognostic value in cardiovascular imaging.

Keywords

Cardiovascular PET Tracers

Radiotracers

PET flow tracers

N13-Ammonia

Rubidium82

F18-Flurpiridaz

Compartmental modeling

Myocardial blood flow

Spatial resolution

Quantification